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Abstract
Early diagnosis is very important to improve the survival rate of patients with gastric cancer and to understand the
biology of cancer. In order to meet the clinical demands for early diagnosis of gastric cancer, we developed
a disposable easy-to-use electrochemical microfluidic chip combined with multiple antibodies against six kinds
of biomarkers (carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), Helicobacter pylori CagA
protein (H.P.), P53oncoprotein (P53), pepsinogen I (PG I), and PG-II). The six kinds of biomarkers related to gastric cancer
can be detected sensitively and synchronously in a short time. The specially designed three electrodes system enables
cross-contamination to be avoided effectively. The linear ranges of detection of the electrochemical microfluidic chip
were as follows: 0.37–90 ng mL−1 for CEA, 10.75–172 U mL−1 for CA19-9, 10–160 U L−1 for H.P., 35–560 ng mL−1 for
P53, 37.5–600 ng mL−1 for PG I, and 2.5–80 ng mL−1for PG II. This method owns better sensitivity compared
with enzyme-linked immunosorbent assay (ELISA) results of 394 specimens of gastric cancer sera. Furthermore,
we established a multi-index prediction model based on the six kinds of biomarkers for predicting risk of gastric cancer.
In conclusion, the electrochemical microfluidic chip for detecting multiple biomarkers has great potential in applications
such as early screening of gastric cancer patients, and therapeutic evaluation, and real-time dynamic monitoring the
progress of gastric cancer in near future.
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Background
Gastric cancer (GC) is the second most common can-
cer and the third leading cause of cancer-related death
in China [1–3]. It remains very difficult to cure effect-
ively, primarily because most patients present with ad-
vanced diseases. Up to date, gastric cancer prognosis is
very poor with 5-year survivals below 24 %. Multidis-
ciplinary treatment is used to improve treatment effi-
cacy of advanced stage of GC. However, it has been
proven that gastric cancer is not particularly sensitive
to current chemotherapy agents, which is closely asso-
ciated with intrinsic or acquired properties of gastric
cancer cells. Therefore, discovery of early gastric can-
cer has become main pathway to improve the thera-
peutic efficacy.
We have tried to establish an early gastric cancer
pre-warning and diagnosis system since 2005 [4]. We
hoped to find early gastric cancer cells in vivo by
multi-mode targeting imaging and serum biomarker
detection techniques. Our previous studies showed
that subcutaneous and in situ gastric cancer tissues
with 5 mm in diameter could be recognized and
treated by using multifunctional nanoprobes such as
breast cancer-associated antigen 1(BRCAA1)-conju-
gated fluorescent magnetic nanoparticles [5], human
epidermal growth factor receptor-2 (HER-2) antibody-
conjugated Rnase A (ribonuclease A)-associated CdTe
quantum dots [6], folic acid-conjugated upper conversion
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nanoparticles [7], Arg-Gly-Asp (RGD) peptide-conjugated
gold nanorods [8], ce6-conjugated carbon dots [9],
ce6-conjugated Au nanoclusters (AuNCs) [10], HAI-
178 antibody-conjugated fluorescent magnetic nano-
particles [11], CD44 monoclonal antibody-conjugated
gold nanostars [12], and RNA nanoparticles carrying
both ligand and siRNA [13]. However, clinical translation
of these prepared nanoprobes still exist great challenge be-
cause their biosafety still needs a long term evaluation.
We also screened out some breath biomarkers associated
with gastric cancer [14], and established some methods
and devices to detect these biomarkers [15–17]. We also
developed a giant magneto resistive (GMR) microfluidic
system to detect the circulation gastric cancer cells [18].
However, up to date, serum biomarker detection to screen
or find early gastric cancer is still most effective method.
In the past decades, detection of serum tumor bio-
markers has always been an important mean of diagnosis
of various cancers. However, accepted unique serological
biomarker for gastric cancer, like as Alpha-fetoprotein
(AFP) for hepatocellular carcinoma (HCC) [19], remains
absent. For this reason, combined detection of multiple
serological biomarkers is an alternative effective method
for predicting risk of gastric cancer. Several serological
biomarkers based on a lot of literature can be used for
early diagnosis of gastric cancer so far. Mutations in the
tumor suppressor gene p53 are the most commonly ob-
served in human cancers. In the serum of healthy sub-
jects, the presence of P53 protein is extremely rare.
Mutations in this gene cause an accumulation of non-
functional proteins. The accumulated proteins are de-
tectable in tissues, sloughed cells, blood, and other body
fluids [20]. The p53 gene mutations are significantly
correlated with P53 protein over-expression and con-
tribute to genetic predisposition in gastric cancer pa-
tients [21–23]. Carcinoembryonic antigen (CEA) is an
acknowledged member of immunoglobulin superfamily,
with a role as an intracellular adhesion molecule [24]. A
high-serum CEA is associated with a number of malig-
nancies, including colorectal, breast, gastric, and pan-
creatic cancers [25]. CA19-9 has a positive correlation
with depth of invasion, nodal involvement, and periton-
eal metastasis in gastric adenocarcinoma [26, 27]. In
addition, many studies have shown that serum pepsin-
ogen I (PG I) [28, 29], pepsinogen II (PG II) [30], PG I/PG
II ratio [31, 32], and Helicobacter pylori (H. P.) [33–35]
are also associated with an increased risk of gastric
cancer. So, combined detection of above serum bio-
markers is helpful to enhance accuracy of predicting
gastric cancer risk.
Enzyme-linked immunosorbent assay (ELISA) is widely
used for clinical cancer diagnosis; nevertheless, these or-
dinary ELISA kits for single biomarker are not suitable for
individual diagnosis, especially for patients with risk of
gastric cancer. Moreover, the ELISA kits for batch
samples from the different patients not only easily expose
to cross-contamination, but also the operation is com-
plicated. Self-assembled monolayers (SAMs) are widely
used to immobilize biomolecules on gold surfaces [36].
The self-assembly process is the spontaneous organization
of substances into gold surfaces. SAMs of different sub-
stances have frequently utilized for development of bio-
sensors, microarrays, biochips, and molecular switches
[37]. Microfluidic technology seeks to improve analysis
time, decreasing the consumption of sample and reagents,
diminishing the risk of contamination, consuming less
power, and sensitivity through automation, integrating
multiplexing analysis, and especially portability to provide
the possibility of point-of-care applications [38–40]. In
comparison with the methods based on chemilumines-
cence, fluorescence, electrochemiluminescence, or quartz
crystal microbalance, electrochemical immunoassay has
attracted tremendous interest due to its high sensitivity,
low cost, simple instrumentation, and good portability
[41]. All the same, this electrochemical immunoassay still
have complicated preparation processes, high cost bring
about difficult to clinical application and poor universality.
In this study, in order to meet the clinical demands
and to overcome the above disadvantages, we develop
a disposable easy-to-use electrochemical microfluidic
chip combined with multiple antibodies for early diagnosis
of gastric cancer. Optimized design of three electrodes
system can effectively avoid cross disturbance. And com-
bined detection based on multiple antibodies can improve
the early diagnostic rate of gastric cancer. Accordingly, the
unique electrochemical microfluidic chip owns great po-
tential in application for gastric cancer early screening in
near future.
Methods
Fabrication of Electrochemical Microfluidic Chip
Microelectrodes were fabricated on a glass wafer using
standard micro-fabrication techniques. Chromium (Cr
100 nm)/gold (Au 200 nm) film stack was deposited on
the glass wafers using electron-beam evaporator (L-H
Inc.). Cr layer acts as the adhesion promoter for the
gold film. The Au microelectrodes were formed on a
glass wafer using a lift-off process as follows: a photo-
resist (AZ4903) was spin coated onto a glass wafer and
then patterned by photolithography. Next, Au/Cr (200 nm/
100 nm) was deposited onto the patterned glass wafer
by electron-beam evaporator. After that, the electrodes
on the glass substrate were completed by removing the
photoresist from underneath the deposited metal using
a solvent. Lift off was performed via sonication in acet-
one followed by rinsing in deionized water. Individual
chips were cut using cutting machine (K&S Inc.). Each
of the chips included six groups of electrodes. One
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group of detection electrode was comprised of working
electrode, pseudo reference, and counter electrode. The
surfaces of the Au electrodes were immobilized with
antibodies by chemical process according to the follow-
ing section of methods. PDMS (polydimethylsiloxane)
molds were fabricated by photolithography of SU-8
photoresist on Si wafers and the thickness of SU-8 is
30 μm. PDMS pre-polymer and curing agents were
mixed, degassed and poured onto the molds, and cured
at 60 °C for 3 h. Individual PDMS chips were cut and
inlet/outlet holes were punched. Briefly, PDMS surfaces
were exposed to oxygen plasma (DQJ-150, Shanghai,
China). PDMS channels were assembled together with
glass chips Fig. 1.
Antibodies Immobilization
Firstly, the electrodes were washed ultrasonically in
ethanol for 5 min and then were immersed in piranha
solution (H2O2(v)/H2SO4(v) = 1/3) for 5 min to clean
the surfaces. Subsequently, the electrodes were rinsed
with sterile ultrapure water for 10 times and were
dried with nitrogen. After dripping 2 μL mercaptoace-
tic acid (Sigma, USA) on the surface of each working
electrode, the chip was placed in an airtight container
for 1 h to form a carboxylic self-assembled monolayer.
Then, the chip was rinsed with ethanol and was dried
with nitrogen gently. The carboxyl groups on the sur-
face of electrodes were activated with 0.4 M 1-ethyl-
3-[3-dimethylaminopropyl] carbodiimide hydrochloride
(EDC) and 0.2 M N-hydroxysuccinimide (NHS) solu-
tion prepared in a 0.1 M phosphate buffer solution
(PBS, pH = 7.4) for 20 min for immobilizing antibodies.
After rinsing with PBS buffer and drying with nitrogen,
six kinds of antibodies (anti-CEA, anti-CA19-9, anti-
H.P., anti-P53, anti-PG I, and anti-PG II) solutions were
respectively dripped on the surfaces of six working
electrodes and incubated at 37 °C for 3 h. Lastly, the
immunological chip was obtained after incubating 0.5 %
BSA (bovine serum albumin) at 37 °C for 1 h to block
non-specific binding sites and rinsing with 0.01 M PBS
buffer. The prepared chips were stored at 4 °C for next
immunoreaction and electrochemical detection.
Immunological Reaction and Electrochemical Signal
Detection
The immunological reaction was carried out as follows:
Firstly, the six kinds of biomarkers related to gastric
cancer (CEA, CA19-9, H.P., P53, PG I, and PG II) solu-
tions were respectively prepared in a series of concen-
tration with phosphate buffer solution (PBS, pH = 7.4)
(Table. 1). Secondly, the biomarker solutions with series
of concentrations were injected into the microfluidic
chips and incubated at 37 °C for 30 min to form the
antigen–antibody immune complexes [42–44]. In order
Table 1 The different concentration of biomarkers in PBS
Biomarkers Concentration gradient
CEA (ng mL−1) 0.37 1.11 3.33 10 30 90
CA19-9 (U mL−1) 10.75 21.5 43 86 172
H.P. (U L−1) 5 10 20 40 80 160
P53 (pg mL−1) 35 70 140 280 560
PG I (ng mL−1) 37.5 75 150 300 600
PG II (ng mL−1) 2.5 5 10 20 40 80
Fig. 1 Overview of the electrochemical microfluidic chip fabrication process
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to remove unbound biomarkers, PBS was subsequently
injected into microfluidic chip for rinsing microchannel
and microchamber at 100 μL min−1 for 5 min.
After immunological reaction, antigen–antibody com-
plexes formed on the surface of working electrodes were
simultaneously detected by differential pulse voltamme-
try (DPV) with an electrochemical analyzer (CHI-1030,
Chenhua, China). All electrochemical measurements were
performed in 5 mM K3[Fe(CN)6]/K4[Fe(CN)6]-PBS (pH =
7.4) solution from −0.3 to 0.6 V at scan rate 50 mV s−1.
Comparing with ELISA and Establishing Multi-index
Prediction Model
Three hundred ninety-four specimens of gastric cancer
sera were collected from Tangdu Hospital, East-southern
Hospital affiliated to East-southern University, Xi’an
Central Hospital. Gastric cancer patients were identified
by pathological doctor. ELISA kits (Boster, Wuhan, China)
for CEA, CA19-9, H.P., PG I, PG II, and P53 were pur-
chased from Shanghai Reagent Company, all ELISA kits
obtained the permission certification by China Food and
Drug Administration (CFDA). All specimens were exam-
ined by using ELISA method and electrochemical method
in Department of Clinical Biochemistry, No. 1 People
Hospital affiliated to Shanghai Jiao Tong University.
Statistical Analysis
All results are reported as means ± SD. And all data
were analyzed by statistical methods including correl-
ation and F test with SPSS 22.0 (IBM Corp., USA).
The level of P < 0.05 was regarded as significant.
Results and Discussion
Electrochemical Microfluidic Chip
As shown in Fig. 2b, electrochemical microfluidic chips
(ECMC) were fabricated successfully. It consists of six
Fig. 2 a Schematic illustration of the electrochemical microfluidic chip. b Picture of electrochemical microfluidic chip. c SEM image of surface of
work electrode
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detection areas for six different kinds of biomarkers.
Every detection area was an independent gold three-
electrode unit including working electrode, pseudo refer-
ence, and counter microelectrodes. As shown in Fig. 2c,
the surface of electrode formed a nano-film consist of Au
nanoparticles. The size of a nanoparticle is 50 ± 2 nm. The
volume of single chamber is about 0.2–0.25 μL. Six kinds
of antibodies against CEA, CA19-9, H.P., PG I, PG II, and
P53 were respectively immobilized on surfaces of working
electrodes by chemical coupling (Fig. 2a).
Experimental Results of Six Kinds of Biomarkers
The electrodes of chips were characterized by differential
pulse voltammetry (DPV). As shown in Fig. 3, the elec-
trons transfer ability of working electrodes weakened ob-
viously compared with bare electrodes (black line) after
antibodies immobilization (blue line). After BSA block-
ing at 37 °C for 1 h (red line), the electrons transfer
ability further weakened, but a little. In this study, the
DPA signals of electrodes modified with antibodies
after BSA blocking were defined as control signals. The
control signals of working electrodes for detecting six
kinds of biomarkers were −347 nA for CEA, −103 nA
for CA19-9, −447 nA for H.P., −298 nA for P53, −373 nA
for PG I, and −548 nA for PG II, respectively. All detect-
able signals stronger than the corresponding control sig-
nals were defined as positive signals.
The six kinds of biomarkers solutions were respectively
injected into the microchannels and incubated at 37 °C for
30 min. DPV responses of K3[Fe(CN)6]/K4[Fe(CN)6] PBS
were measured by multiplex electrochemical work sta-
tion. As shown in Fig. 4, the oxidation currents of Fe2+
Fig. 3 Typical differential pulse voltammograms of the electrode modified by antibodies: a CEA, b CA19-9, c H.P., d P53, e PG I, and f PG II
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decreased with the biomarkers concentrations in-
creased, and there was a positive correlation between
the oxidation peak currents and the concentration of
analytes. As shown in Table 2, the linear detection ranges
were 0.37–90 ng mL−1 for CEA, 10.75–172 U mL−1 for
CA19-9, 10–160 U L−1 for H.P., 35–560 ng mL−1 for P53,
37.5–600 ng mL−1 for PG I, and 2.5–80 ng mL−1 for PG
II, respectively. And the corresponding correlation coeffi-
cients were 0.961, 0.983, 0.942, 0.971, 0.934, and 0.972, re-
spectively. The detection limits, the minimum detectable
signal higher than control signals, are 0.37 ng mL−1 for
CEA, 10.75 U mL−1 for CA19-9, 5 U L−1 for H.P.,
35 pg mL−1 for P53, 37.5 ng mL−1 for PG I, and
2.5 ng mL−1 for PG II, respectively. Although the de-
tection point (5 U L−1 for H.P.) was not in the linear
range, it still can generate a detectable response sig-
nal (Fig. 4c).
As shown in the Fig. 4, electrochemical signals of
electrodes weakened owing to formation of antibody–
antigen immune complexes. The immune complexed
impeded of electrons transporting between the surface
of electrodes and K3[Fe(CN)6]/K4[Fe(CN)6]-PBS solu-
tion. In addition, external disturbance can efficiently
Fig. 4 Linear detection ranges of six kinds of biomarkers by differential pulse voltammetry. a CEA, b CA19-9, c H.P., d P53, e PG I, and f PG II
Table 2 The linear detection range and detection limits of
biomarkers
Biomarkers Detection range Detection limit
CEA (ng mL−1) 0.37–90 0.37
CA19-9 (U mL−1) 10.75–172 10.75
H.P. (U L−1) 10–160 5
P53 (pg mL−1) 35–560 35
PG I (ng mL−1) 37.5–600 37.5
PG II (ng mL−1) 2.5–80 2.5
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be avoided by independent three microelectrodes sys-
tem and closed micro-chambers that are conducive to
the stable electrochemical signal acquisition.
The currently electrochemical immunoassay is fo-
cused on biomarkers immobilized on nanomaterials
for enhancing intensity and specificity of signal [45].
The traditional electrochemical immunoassay relied
on electroactive materials and enzyme, such as HRP
(horseradish peroxidase), thionine, prussian blue, and
so on [46, 47]. These reported methods have inevit-
able limitations such as specific materials and are dif-
ficult to acquire stable signals in clinical application.
At present, most of multiplex detection always detect
two or three biomarkers [46, 48, 49], which cannot
meet the clinical needs. This work has adopted a
novel solution to avoid the above trouble. We immobi-
lized six kinds of antibodies on the surface of microelec-
trodes separated by micro-chambers, respectively. An
electrochemical microfluidic chip has six detection
areas, each of detection area included a working elec-
trode, a pseudo reference, a counter electrode, and a
micro-chamber. Independent three electrodes system
in micro-chambers avoided the crosstalk between the
working electrodes. And this chip can directly detect
biomarkers captured by antibodies on the surface of
microelectrodes and generate response signals for early
diagnosis of gastric cancer.
Comparison with ELISA and Establishment of Multi-index
Prediction Model
In order to evaluate the performance of ECMC in clin-
ical application, 394 serum specimens of gastric cancer
patients collected were used to measure the serum
CEA, CA19-9, H.P., P53, PG I, and PG II levels. The
normal cut-off values of CEA, CA19-9, P53, H.P., PG I,
PG II, and PG I/PG II are 5.0 ng mL−1, 37 U mL−1,
10 U L−1, 150 pg mL−1, 70 ng mL−1, 11.5 ng mL−1, and
3.0, respectively [30, 31, 50–52]. As shown in Table 3,
for electrochemical microfluidic chip (ECMC), the posi-
tive rates of CEA, CA19-9, H.P., P53, PG I, PG II were
7.11, 38.07, 68.78, 59.65, 74.11, and 76.74 %, respect-
ively. For ELISA, the positive rates of CEA, CA19-9,
H.P., P53, PG I, PG II were 4.57, 33.76, 52.03, 51.52,
66.75, and 65.74 %, respectively. It was evident that
ECMC possessed higher detection sensitivity than ELISA.
To explore the correlation between the six kinds of
biomarkers and gastric cancer, we established a multi-
index prediction model by multiple linear regression
based on 394 serum samples of gastric cancer patients.
The multi-index model based on large samples can be
used to predict risk of gastric cancer more accurately and
effectively in clinical screening.
Y ¼ bþ Ai  X j
Ai (i = 1, 2, 3, 4, 5, 6), Xj (j = 1, 2, 3, 4, 5, 6) represented
regression coefficient and detection value of six kinds of
biomarkers, respectively (Table 4).
Conclusions
In summary, a novel electrochemical immune detec-
tion system based on microfluidic chip was developed
for simultaneous detecting multiple biomarkers (CEA,
CA19-9, H.P., P53, PG I, and PG II) for early diagno-
sis of gastric cancer. The experimental construction
and the DPV detection were based on the fact that
the formed antibody–antigen immune complexes re-
tarded the electron transfer tunnel of gold electrodes.
Highlights of this work could be summarized as fol-
lows: (1) Simultaneous detection for multiple bio-
markers has higher efficiency than single biomarker
of ELISA. (2) The proposed microfluidic chip with in-
dependent reaction micro-chambers can contribute to
stable detection signal and minimal false positive
compared with conventional protein microchip sys-
tems. (3) Microfluidic chip has low detection cost be-
cause of low reagent consumption. (4) The ECMC
has higher detection sensitivity and is very suitable
for clinical diagnosis. (5) The multi-index prediction
model can be used to predict risk of gastric cancer
more accurately and effectively.
Table 3 Detection performance comparison between ECMC and ELISA
Biomarkers ECMC ELISA Normal reference ranges
CEA 28/394 (7.11 %) 18/394 (4.57 %) ≤5.0 ng mL−1
CA19-9 150/394 (38.07 %) 133/394 (33.76 %) ≤37 U mL−1
H.P. 271/394 (68.78 %) 205/394 (52.03 %) ≤10 U L−1
P53 235/394 (59.65 %) 203/394 (51.52 %) ≤150 pg mL−1
PG I 292/394 (74.11 %) 263/394 (66.75 %) ≤70 ng mL−1
PG II 301/394 (76.40 %) 259/394 (65.74 %) ≤11.5 ng mL−1
Table 4 Values of b and regression coefficient (Ai)
b A1 A2 A3 A4 A5 A6
9.24 5.12 1.15 –3.41 –2.58 4.31 6.83
E-01 E-06 E-04 E-06 E-05 E-05 E-06
E scientific notation
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BSA: bovine serum albumin; CA19-9: carbohydrate antigen 19-9;
CEA: carcinoembryonic antigen; DPV: differential pulse voltammetry;
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carbodiimide hydrochloride; ELISA: enzyme-linked immunosorbent assay;
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solution; PDMS: polydimethylsiloxane; PG I: pepsinogen I; PG II: pepsinogen II;
SAMs: self-assembled monolayers.
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